Blackstone Files 13D/A for Autolus Therapeutics

Ticker: BX · Form: SC 13D/A · Filed: 2024-05-21T00:00:00.000Z

Sentiment: neutral

Topics: ownership-change, sec-filing, biotech

Related Tickers: AUTL

TL;DR

Blackstone updated its stake in Autolus Therapeutics plc on 5/21/24.

AI Summary

Blackstone Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of Autolus Therapeutics plc. The filing, dated May 21, 2024, details Blackstone's stake in the company, which is involved in the biological products sector.

Why It Matters

This filing signals a potential shift in significant ownership for Autolus Therapeutics, which could impact its stock price and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can precede significant market movements or strategic changes for the company.

Key Players & Entities

FAQ

What is the specific percentage of Autolus Therapeutics plc shares beneficially owned by Blackstone Inc. as of May 21, 2024?

The filing does not explicitly state the exact percentage of beneficial ownership as of May 21, 2024, but it is an amendment to a Schedule 13D, indicating a change in ownership.

What is the primary business of Autolus Therapeutics plc?

Autolus Therapeutics plc is primarily involved in the biological products sector, specifically 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.

What is Blackstone Inc.'s business classification?

Blackstone Inc.'s business classification is 'INVESTMENT ADVICE' with SIC code 6282.

When was the last name change for Blackstone Inc. as a company?

Blackstone Inc. had a name change on August 6, 2021.

What is the business address of Autolus Therapeutics plc?

The business address of Autolus Therapeutics plc is THE MEDIAWORKS, 191 WOOD LANE, LONDON, W12 7FP.

From the Filing

0001193125-24-143963.txt : 20240521 0001193125-24-143963.hdr.sgml : 20240521 20240521163052 ACCESSION NUMBER: 0001193125-24-143963 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 GROUP MEMBERS: BLACKSTONE CLARUS GP L.L.C. GROUP MEMBERS: BLACKSTONE GROUP MANAGEMENT L.L.C. GROUP MEMBERS: BLACKSTONE HOLDINGS I L.P. GROUP MEMBERS: BLACKSTONE HOLDINGS I/II GP L.L.C. GROUP MEMBERS: BLACKSTONE LIFE SCIENCES ASSOCIATES V (CYM) L.L.C. GROUP MEMBERS: BXLS V - AUTOBAHN L.P. GROUP MEMBERS: STEPHEN A. SCHWARZMAN SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-90550 FILM NUMBER: 24969881 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Blackstone Inc. CENTRAL INDEX KEY: 0001393818 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] ORGANIZATION NAME: 02 Finance IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: (212) 583-5000 MAIL ADDRESS: STREET 1: 345 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: Blackstone Inc DATE OF NAME CHANGE: 20210806 FORMER COMPANY: FORMER CONFORMED NAME: Blackstone Group Inc DATE OF NAME CHANGE: 20190628 FORMER COMPANY: FORMER CONFORMED NAME: Blackstone Group L.P. DATE OF NAME CHANGE: 20070320 SC 13D/A 1 d841342dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 ** (CUSIP Number) John G. Finley Blackstone Inc. 345 Park Avenue New York, New York 10154 (212) 583-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 17, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. ** There is no CUSIP number assigned to the ordinary shares. CUSIP number 05280R 100 has been assigned to the American Depositary Shares of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “AUTL.” Each American Depositary Share represents the right to receive one ordinary share. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of

View on Read The Filing